# CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

> **NCT05704192** · — · UNKNOWN · sponsor: **Zhongda Hospital** · enrollment: 373 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Portal Hypertension

## Interventions

- **PROCEDURE:** TACE ± Systemic therapy

## Key facts

- **NCT ID:** NCT05704192
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-04
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 373 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704192, "CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05704192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*